Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hypoferritinemia Without Anemia Among Reproductive Age Females
Sponsor: Akram Medical Complex
Summary
The goal of this randomized controlled trial is to compare the treatment outcomes of oral iron supplementation (Group A) versus Intravenous (IV) iron supplementation (Group B) versus no treatment (Group C) on the serum ferritin level and to determine the outcomes in the severity of symptoms of HWA, among reproductive age females (age 18-45) with hypoferritinemia without Anemia (HWA), after four months of the start of the intervention. Participants will: * Randomly divided into 3 groups (A, B and C) to receive treatment. * 100 patients will be allocated to each of the three study groups i.e., group A, B and C. The participants of Group A will get oral Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg (Fersip) daily for three months, participants of group B will get IV Ferric Carboxymaltose (Ferinject) for 03 months (3 doses) and Group C will get no treatment.
Official title: Hypoferritinemia Without Anemia Among Reproductive Age Females: Frequency, Determinants and Treatment Outcomes
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
1331
Start Date
2022-10-10
Completion Date
2025-10-16
Last Updated
2026-05-19
Healthy Volunteers
Yes
Interventions
Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg
01 tablet daily for 03 months, This is assigned to Group A.
Ferric Carboxymaltose
03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
Locations (4)
Fatima Memorial Hospital
Lahore, Punjab Province, Pakistan
General Hospital Lahore
Lahore, Punjab Province, Pakistan
Gulab Devi Hospital
Lahore, Punjab Province, Pakistan
Sir Gangaram Hospital
Lahore, Punjab Province, Pakistan